Form 4: Terns Pharma CMO Granted RSUs, Stock Options

Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, was granted 56,250 Restricted Stock Units and 112,500 stock options as part of an incentive plan.

Summary

• Emil Kuriakose, Chief Medical Officer of Terns Pharmaceuticals, Inc. (TERN), was granted equity awards.
• The grants include 56,250 Restricted Stock Units (RSUs) and 112,500 stock options.
• The RSUs were granted at a price of $0.00 per share.
• The stock options have an exercise price of $37.18 per share.
• Both the RSUs and stock options begin vesting on January 1, 2026.
• Vesting for both awards is structured with 25% vesting on the first anniversary (January 1, 2027).
• RSUs vest 1/16th quarterly thereafter, fully vesting on the fourth anniversary (January 1, 2030).
• Stock options vest 1/48th monthly thereafter, fully vesting on the fourth anniversary (January 1, 2030).
• Following these transactions, Emil Kuriakose beneficially owns 106,615 shares of common stock and 112,500 derivative securities (stock options).
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive is generally a positive sign for executive alignment and retention, though it implies future dilution.

Positives

• Grants align the Chief Medical Officer's interests with long-term shareholder value.
• Equity awards serve as a significant incentive for executive retention and performance.
• The use of a Rule 10b5-1 plan indicates a pre-planned, structured approach to executive compensation.

Negatives

• Potential for future dilution of existing shareholders as RSUs vest and options are exercised.

Risks

• Future stock price performance could impact the value of the options and RSUs, potentially affecting executive motivation if the price declines significantly.
• The long vesting schedule means the executive's full compensation from these grants is contingent on continued employment and company performance over several years.

Future Outlook

NA

Industry Context

This is a routine disclosure of executive compensation in the biotechnology/pharmaceutical industry, where equity grants are a standard component of executive pay packages designed to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders: Potential future dilution upon vesting and exercise of awards; improved alignment of executive incentives with long-term shareholder value.
• Employees: Standard executive compensation practices can set a precedent or benchmark for other employee incentive programs.
• Executive (Emil Kuriakose): Significant increase in potential future wealth, strong incentive for long-term performance and retention.

Next Steps

• Vesting of 25% of RSUs and stock options on January 1, 2027.
• Quarterly vesting of RSUs (1/16th) and monthly vesting of stock options (1/48th) after the first anniversary.
• Full vesting of all RSUs and stock options by January 1, 2030.
• Potential exercise of stock options by January 13, 2036.

Key Dates

Keywords

Terns Pharmaceuticals, TERN, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation, Chief Medical Officer, Emil Kuriakose, 10b5-1 Plan